The National Medical Products Administration (NMPA) issued a list of the second group of key projects for China's drug regulatory science action plan based on the summary of the implementation of the first group on June 24.

Departments and related affiliated institutions of the NMPA were urged to speedily formulate implementation plans in accordance with related requirements and to further improve their drug regulatory capacities, so as to speed up the marketization of innovative products and better meet the needs of public health.